Markets
CNC

Validea's Top Five Healthcare Stocks Based On Martin Zweig - 10/18/2020

The following are the top rated Healthcare stocks according to Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.

CENTENE CORP (CNC) is a large-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Martin Zweig is 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Centene Corporation is a healthcare company. The Company provides a portfolio of services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals. The Company operates through two segments: Managed Care and Specialty Services. The Company's Managed Care segment provides health plan coverage to individuals, through government subsidized programs, including Medicaid, the State Children's Health Insurance Program (CHIP), Long Term Care, Foster Care, dual-eligible individuals (Duals) and the Supplemental Security Income Program, also known as the Aged, Blind or Disabled Program (ABD), Medicare, and Health Insurance Marketplace. Its Specialty Services segment consists of its specialty companies offering a range of healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups and other commercial organizations, as well as to its own subsidiaries.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

P/E RATIO:PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH:PASS
SALES GROWTH RATE:PASS
CURRENT QUARTER EARNINGS:PASS
QUARTERLY EARNINGS ONE YEAR AGO:PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER:PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS:FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:PASS
EARNINGS PERSISTENCE:PASS
LONG-TERM EPS GROWTH:PASS
TOTAL DEBT/EQUITY RATIO:PASS
INSIDER TRANSACTIONS:PASS

Detailed Analysis of CENTENE CORP

Full Guru Analysis for CNC>

Full Factor Report for CNC>

ALPHA PRO TECH, LTD. (APT) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: ALPHA PRO TECH, LTD. (Alpha Pro Tech) is in the business of protecting people, products and environments. The Company is engaged in developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets through its subsidiary, Alpha Pro Tech, Inc. Its products are grouped into three segments: Building Supply, which consists of construction weatherization products, such as housewrap and synthetic roof underlayment, as well as other woven material; Disposable Protective Apparel, which consists of disposable protective apparel, such as shoecovers, bouffant caps, gowns, coveralls, lab coats, frocks and other miscellaneous products, and Infection Control, which consists of face masks and eye shields. The Company also manufactures a line of building supply construction weatherization products through its subsidiary, Alpha ProTech Engineered Products, Inc.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

P/E RATIO:PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH:FAIL
SALES GROWTH RATE:PASS
CURRENT QUARTER EARNINGS:PASS
QUARTERLY EARNINGS ONE YEAR AGO:PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER:PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS:FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:PASS
EARNINGS PERSISTENCE:FAIL
LONG-TERM EPS GROWTH:PASS
TOTAL DEBT/EQUITY RATIO:PASS
INSIDER TRANSACTIONS:PASS

Detailed Analysis of ALPHA PRO TECH, LTD.

Full Guru Analysis for APT>

Full Factor Report for APT>

CHEMED CORPORATION (CHE) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Martin Zweig is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company's VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. VITAS is the provider of hospice services in an industry dominated primarily by small, non-profit, community-based hospices. VITAS provides hospice care to Medicare beneficiaries participating in these managed care programs. A portion of its VITAS business is operated in the state of Florida. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

P/E RATIO:PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH:FAIL
SALES GROWTH RATE:FAIL
CURRENT QUARTER EARNINGS:PASS
QUARTERLY EARNINGS ONE YEAR AGO:PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER:PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:PASS
EARNINGS PERSISTENCE:FAIL
LONG-TERM EPS GROWTH:PASS
TOTAL DEBT/EQUITY RATIO:PASS
INSIDER TRANSACTIONS:PASS

Detailed Analysis of CHEMED CORPORATION

Full Guru Analysis for CHE>

Full Factor Report for CHE>

BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Martin Zweig is 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

P/E RATIO:PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH:FAIL
SALES GROWTH RATE:PASS
CURRENT QUARTER EARNINGS:PASS
QUARTERLY EARNINGS ONE YEAR AGO:PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER:PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS:FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:FAIL
EARNINGS PERSISTENCE:PASS
LONG-TERM EPS GROWTH:PASS
TOTAL DEBT/EQUITY RATIO:PASS
INSIDER TRANSACTIONS:PASS

Detailed Analysis of BIOGEN INC

Full Guru Analysis for BIIB>

Full Factor Report for BIIB>

MERIDIAN BIOSCIENCE, INC. (VIVO) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

P/E RATIO:PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH:PASS
SALES GROWTH RATE:PASS
CURRENT QUARTER EARNINGS:PASS
QUARTERLY EARNINGS ONE YEAR AGO:PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER:PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS:FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS:PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:PASS
EARNINGS PERSISTENCE:FAIL
LONG-TERM EPS GROWTH:FAIL
TOTAL DEBT/EQUITY RATIO:PASS
INSIDER TRANSACTIONS:PASS

Detailed Analysis of MERIDIAN BIOSCIENCE, INC.

Full Guru Analysis for VIVO>

Full Factor Report for VIVO>

More details on Validea's Martin Zweig strategy

About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in "Dirty Harry", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.

About Validea: Validea is an investment research service that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CNC APT CHE BIIB VIVO

Latest Markets Videos

    Validea

    At Validea we believe the best way to outperform the market is to follow the investment factors and strategies that have done so over long periods of time. Since 2003, our team has been dedicated to bringing the fundamental strategies of great investors and academics to the professional and retail investment communities via the tools, portfolios and research found on Validea.

    Learn More